Inicia sesión Registrate Mi Biblioteca idioma

Idioma

biblioteca idioma abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará la selección de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por International Parkinson & Movement Disorder Society.

2012

4257 ARTíCULOS , VIENDO DEL 1 AL 15

PUBMED

Xanthine Derivatives

2020 Jul 18. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.

0

0

0

PUBMED

Atomoxetine Therapy and CYP2D6 Genotype

Dean L.

2015 Sep 10 [updated 2020 Jun 29]. In: Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–.

0

0

0

PUBMED

A neuroprotective role of the human uncoupling protein 2 (hUCP2) in a Drosophila Parkinson's disease model.

Islam R, Yang L, Sah M, Kannan K, Anamani D, Vijayan C, Kwok J, Cantino ME, Beal MF, Fridell YW.

Neurobiol Dis. 2012 Apr;46(1):137-46. doi: 10.1016/j.nbd.2011.12.055.

0

0

0

PUBMED

[Diagnosis of dopa-responsive dystonia after 34 years: complete remission after L-dopa treatment].

Reichel G, Stenner A.

Nervenarzt. 2012 Jun;83(6):772-4. doi: 10.1007/s00115-011-3423-3. German. No abstract available.

0

0

0

PUBMED

Cerebellar ataxia rehabilitation trial in degenerative cerebellar diseases.

Miyai I, Ito M, Hattori N, Mihara M, Hatakenaka M, Yagura H, Sobue G, Nishizawa M; Cerebellar Ataxia Rehabilitation Trialists Collaboration..

Neurorehabil Neural Repair. 2012 Jun;26(5):515-22. doi: 10.1177/1545968311425918.

0

0

0

PUBMED

The role of GRK6 in animal models of Parkinson's disease and L-DOPA treatment.

Managò F, Espinoza S, Salahpour A, Sotnikova TD, Caron MG, Premont RT, Gainetdinov RR.

Sci Rep. 2012;2:301. doi: 10.1038/srep00301.

0

0

0

PUBMED

Stability of resting fMRI interregional correlations analyzed in subject-native space: a one-year longitudinal study in healthy adults and premanifest Huntington's disease.

Seibert TM, Majid DS, Aron AR, Corey-Bloom J, Brewer JB.

Neuroimage. 2012 Feb 1;59(3):2452-63. doi: 10.1016/j.neuroimage.2011.08.105.

0

0

0

PUBMED

THAP1/DYT6 sequence variants in non-DYT1 early-onset primary dystonia in China and their effects on RNA expression.

Cheng FB, Ozelius LJ, Wan XH, Feng JC, Ma LY, Yang YM, Wang L.

J Neurol. 2012 Feb;259(2):342-7. doi: 10.1007/s00415-011-6196-5.

0

0

0

PUBMED

Gamma knife thalamotomy for Parkinson disease and essential tremor: a prospective multicenter study.

Ohye C, Higuchi Y, Shibazaki T, Hashimoto T, Koyama T, Hirai T, Matsuda S, Serizawa T, Hori T, Hayashi M, Ochiai T, Samura H, Yamashiro K.

Neurosurgery. 2012 Mar;70(3):526-35; discussion 535-6. doi: 10.1227/NEU.0b013e3182350893.

0

0

0

PUBMED

What Does the Cochrane Collaboration Say about Rehabilitation for Individuals with Parkinson Disease?

[No authors listed]

Physiother Can. 2012 Fall;64(4):427. doi: 10.3138/ptc.64.4.cochrane. No abstract available.

0

0

0

PUBMED

Gamma butyrolactone (GBL) and gamma valerolactone (GVL): similarities and differences in their effects on the acoustic startle reflex and the conditioned enhancement of startle in the rat.

Marinetti LJ, Leavell BJ, Jones CM, Hepler BR, Isenschmid DS, Commissaris RL.

Pharmacol Biochem Behav. 2012 Jun;101(4):602-8. doi: 10.1016/j.pbb.2012.01.023.

0

0

0

PUBMED

Distinguishing essential tremor from Parkinson's disease: bedside tests and laboratory evaluations.

Thenganatt MA, Louis ED.

Expert Rev Neurother. 2012 Jun;12(6):687-96. doi: 10.1586/ern.12.49. Review.

0

0

0

PUBMED

Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease.

Ballanger B, Klinger H, Eche J, Lerond J, Vallet AE, Le Bars D, Tremblay L, Sgambato-Faure V, Broussolle E, Thobois S.

Mov Disord. 2012 Jan;27(1):84-9. doi: 10.1002/mds.23895.

0

0

0

PUBMED

Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.

Chen C, Cowles VE, Sweeney M, Stolyarov ID, Illarioshkin SN.

J Clin Pharmacol. 2012 Jul;52(7):1069-77. doi: 10.1177/0091270011409232.

0

0

0

Comentarios

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo HONcode Logo WIS

En colaboración con:

Zambon Neuroacademy